Liposome Drug Delivery Market

Liposome Drug Delivery Market (Liposome Structure: Unilamellar Liposomes, Multilamellar Liposomes, and Others; Product: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Liposome Drug Delivery Market Outlook 2031

  • The global industry was valued at US$ 4.7 Bn in 2022
  • It is projected to grow at a CAGR of 8.5% from 2023 to 2031 and reach more than US$ 10.0 Bn by the end of 2031

Analysts’ Viewpoint

Increase in demand for targeted and efficient medical solutions is driving the global liposome drug delivery market. Liposome-based drug delivery systems have a unique advantage, such as encapsulating pharmaceutical agents in lipid bilayers to enhance stability, bioavailability, and precise targeting of diseased cells. Increase in usage in cancer treatment, infectious disease control, and skin care is expected to propel the global liposome drug delivery market demand. Furthermore, surge in demand for targeted drug delivery and streamlined regulatory approval processes are likely to bolster the global liposome drug delivery market development.

Surge in research & development to optimize formulations and overcome production challenges, while balancing innovation and scalability, offers lucrative opportunities to market players. Pharmaceutical companies and biotech firms are collaborating to develop novel liposome drug delivery systems in order to increase market share.

Liposome Drug Delivery Market

Global Liposome Drug Delivery Market Introduction

Liposome drug delivery is an innovative approach in the field of medicine, where pharmaceutical agents are encapsulated within tiny lipid bilayer structures known as liposomes.

These lipid-based vesicles offer several advantages in drug delivery compared to traditional methods. These are able to improve the solubility and stability of poorly soluble drugs, enhancing their effectiveness and reducing side effects.

Liposomes also have the potential to target specific cells or tissues, increasing drug concentration at the desired site, and minimizing damage to healthy cells, which is particularly beneficial in treating diseases like cancer.

Versatility of liposomes is evident in their application across various medical domains, including oncology, infectious diseases, dermatology, and more. These can be engineered to carry a wide range of therapeutic agents such as chemotherapy drugs, antibiotics, and anti-inflammatory compounds.

In October 2021, Evonik Health Care introduced LIPEX Flow, an upgraded version of its LIPEX liposome extruder. This enhanced extruder meets the demand for efficient high-pressure extruders for conventional liposomal drug delivery, benefiting applications such as oncology and vaccines.

Higher Targeted Drug Delivery Demand

Rise in demand for precise and efficient drug delivery is driving the global liposome drug delivery market size. This is ascribed to the pressing need for targeted and site-specific therapeutic interventions.

Traditional drug delivery methods often result in the dispersion of medications throughout the body, leading to unintended side effects and diminished treatment efficacy. In this context, liposomes emerge as a revolutionary solution that empowers medical practitioners to achieve unparalleled precision in treating diseases.

Liposomes, spherical lipid-based vesicles, possess a unique ability to encapsulate pharmaceutical compounds within their bilayer structure. This encapsulation not only shields the drugs from degradation, but also facilitates their transport to specific cells or tissues. This capability addresses a longstanding challenge in medicine – how to administer drugs directly to the intended site of action while sparing healthy cells from exposure. By leveraging this inherent characteristic, liposome based drug delivery minimizes off-target effects, reducing the burden of adverse reactions on patients.

The implications of targeted drug delivery through liposomes are far-reaching. Diseases characterized by complex pathophysiology, such as cancer, require treatments that selectively target malignant cells while preserving the surrounding healthy tissue.

Liposomes excel in this regard, enabling oncologists to administer potent chemotherapeutic agents directly to tumor sites. This not only enhances the therapeutic impact, but also alleviates the debilitating side effects associated with systemic chemotherapy.

The precision offered by liposome-mediated drug delivery extends beyond oncology. In infectious diseases, liposomes can be tailored to seek out specific pathogens, improving antimicrobial therapies' effectiveness. Dermatological conditions, too, benefit from liposomal formulations that can be designed to penetrate skin layers precisely, enhancing the delivery of therapeutic agents.

According to a research study by Jingjing Li et al. published in November 2021, researchers developed lyophilized remdesivir liposomes (Rdv-lips). These liposomes can be reconstituted into a liposomal aerosol for pulmonary delivery, enhancing the in vivo behavior of existing remdesivir cyclodextrin compounds (Rdv-cyc). Liposome encapsulation improved solubility and biocompatibility, ultimately enhancing drug efficacy. As companies continue to develop therapeutics against COVID-19, liposome-based drugs and vaccines are poised to play a crucial role.

Technological Advancements in Various Therapeutic Areas

The global liposome drug delivery market growth can be attributed to a convergence of factors, primarily driven by technological advancements across diverse therapeutic domains and a burgeoning interest in harnessing the potential of liposome-based interventions. This symbiotic relationship between scientific progress and innovative drug delivery strategies has catalyzed a paradigm shift in healthcare.

In the past few years, technological breakthroughs have revolutionized therapeutic approaches across various medical specialties. Fields such as oncology, immunology, and gene therapy have witnessed a surge in novel treatment modalities, capitalizing on cutting-edge research and development. These advancements have paved the way for the integration of liposome drug delivery systems, capitalizing on their unique attributes to enhance treatment outcomes.

Liposomes, with their capacity for encapsulating a wide array of pharmaceutical agents, have seamlessly integrated into these therapeutic areas. In oncology, for instance, the advent of targeted therapies and precision medicine has synergized remarkably well with liposomal technology.

Liposomes can encapsulate potent chemotherapy drugs, shielding healthy tissues from their toxic effects and allowing for concentrated delivery directly to tumor sites. This approach not only bolsters therapeutic efficacy, but also mitigates the distressing side effects associated with conventional treatments.

In the realm of gene therapy, where the manipulation of genetic material holds immense promise for treating genetic disorders, liposome-based carriers offer a safe and efficient means of delivering therapeutic genes into cells. The lipid bilayers of liposomes provide a protective envelope for fragile gene payloads, facilitating their successful transfer and integration into target cells.

The growing interest in liposome drug delivery is evidenced by collaborations between pharmaceutical giants and innovative biotech firms. These partnerships are catalyzing the development of increasingly sophisticated liposomal formulations tailored for specific therapeutic objectives. Such collaborations are not only expanding the liposome drug delivery market, but also fostering a dynamic ecosystem of research and innovation.

Increase in Adoption of Unilamellar Liposomes Revolutionizing Drug Administration

In terms of liposome structure, the unilamellar liposomes segment accounted for the largest global liposome drug delivery market share in 2022. These single-layer lipid vesicles play a pivotal role in revolutionizing drug administration by encapsulating pharmaceutical agents with precision.

Unilamellar liposomes offer enhanced drug stability, controlled release, and targeted delivery to specific cells or tissues. Their versatility spans various therapeutic domains, making them a preferred choice in oncology, infectious diseases, and beyond. As the market continues to expand, unilamellar liposomes remain a cornerstone of advanced drug delivery strategies, underlining their significance in improving treatment efficacy and patient well-being.

Rise in Adoption of Liposomal Doxorubicin in Advanced Cancer Therapy

Based on product, the liposomal doxorubicin segment dominated the global liposome drug delivery market in 2022. Liposomal doxorubicin, a prominent segment in the pharmaceutical landscape, holds a dominant position in advanced cancer therapies.

This encapsulated formulation of the potent chemotherapy drug doxorubicin demonstrates exceptional efficacy in oncology, particularly in treating solid tumors such as breast and ovarian cancers.

By utilizing liposomes, it delivers doxorubicin directly to cancer cells while minimizing damage to healthy tissues, mitigating adverse effects. This targeted approach enhances treatment outcomes, reduces side effects, and exemplifies the strides made in personalized and precision medicine, positioning liposomal doxorubicin as a cornerstone in modern cancer treatment strategies.

Stealth Liposome Technology Fueling Advancements in Personalized Medicine

In terms of technology, the stealth liposome technology segment accounted for significant share of the global liposome drug delivery market in 2022. Stealth liposome technology is reshaping pharmaceutical innovation. By incorporating polyethylene glycol (PEG) coatings, stealth liposomes excel in evading immune detection, extending circulation, and enhancing drug targeting. This innovation finds its prominence in oncology, optimizing drug delivery to cancerous cells while minimizing side effects.

With its versatile potential to encapsulate diverse therapeutics and improve bioavailability, stealth liposome technology drives advancements in personalized medicine and reinforces the market's trajectory toward more efficient, targeted, and patient-centric treatments.

Surge in Demand for Cancer Therapy

Based on application, the cancer therapy segment dominated the global market in 2022. Liposomes offer remarkable precision by directly targeting cancer cells while sparing healthy tissue, reducing side effects.

Liposomal formulations enhance drug bioavailability and enable controlled release, optimizing treatment outcomes. With ongoing research and development, liposome-based cancer therapies continue to expand their applications, driving market growth.

As personalized medicine gains traction, the synergy between liposome drug delivery and cancer therapy positions this segment at the forefront of innovative healthcare solutions. For instance, Foad Rammasi and Neda Esfandiari's May 2021 research emphasized liposomes' flexibility and chemical modification potential in cancer therapeutics. Conjugating polymers, ligands, and molecules enhances liposomes' pharmacological benefits, boosting anticancer treatment efficacy.

Regional Outlook

As per liposome drug delivery market trends, North America dominated the global industry in 2022. The region's supremacy is underpinned by a confluence of factors, including robust research & development initiatives, well-established healthcare infrastructure, and a receptive regulatory environment.

Presence of leading pharmaceutical companies, academic institutions, and research centers further fuels advancements in liposome technology. North America's dominance is particularly evident in its extensive utilization of liposome-based drug delivery systems across various therapeutic domains, ranging from oncology to infectious diseases.

North America's focus on precision medicine and personalized treatment approaches aligns seamlessly with the capabilities of liposomes, which enable targeted and efficient drug delivery, thereby enhancing therapeutic outcomes. Moreover, strategic collaborations between academia, industry, and research institutions in the region play a pivotal role in fostering innovation and accelerating the adoption of liposome drug delivery.

According to liposome drug delivery market analysis, the industry in Asia Pacific is experiencing rapid and robust growth. This momentum can be attributed to a convergence of factors that create a fertile ground for innovation and adoption. The region's burgeoning healthcare infrastructure, combined with increasing investments in research & development, has catalyzed the development and uptake of liposome-based drug delivery systems. The region's diverse and large patient population presents a significant market for novel treatment approaches that enhance therapeutic efficacy while minimizing side effects.

Analysis of Key Players

Leading players in the market are engaged in merger & acquisition, strategic partnerships, and new product launches to expand industry presence.

Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Inc., CELSION Corporation, Abbott, Ipsen Pharma, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited are the prominent players in the market.

Key Developments in Global Liposome Drug Delivery Industry

  • In June 2022, Endo International plc's subsidiary, Endo Ventures Limited (EVL), and Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical firm announced collaboration to commercialize TLC599, an investigational product by TLC. Currently in phase 3 development, TLC599 is an injectable compound designed to address osteoarthritis knee pain, showcasing the continuous efforts to advance treatment options in this therapeutic area.
  • In January 2022, Pfizer, Inc. and Acuitas Therapeutics established a Development and Option agreement. This strategic collaboration empowers Pfizer with a non-exclusive option to license Acuitas' lipid nanoparticle (LNP) technology for potential utilization across up to 10 targets. This technology holds promise for both vaccine and therapeutic development, signifying Pfizer's commitment to innovative solutions and paving the way for novel advancements in the field.

Each of the prominent players has been profiled in the liposome drug delivery market research report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

Global Liposome Drug Delivery Market Snapshot

Attribute Detail

Size in 2022

US$ 4.7 Bn

Forecast (Value) in 2031

More than US$ 10.0 Bn

Growth Rate (CAGR)

8.5%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Mn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Liposome Structure
    • Unilamellar Liposomes
      • Small
      • Large
    • Multilamellar Liposomes
    • Others
  • Product
    • Liposomal Doxorubicin
    • Liposomal Paclitaxel
    • Liposomal Amphotericin B
    • Others
  • Technology
    • Stealth Liposome Technology
    • Non-PEGylated Liposome Technology
    • DepoFoam Liposome Technology
  • Application
    • Fungal Diseases
    • Pain Management
    • Cancer Therapy
    • Viral Vaccines
    • Photodynamic therapy
  • End-user
    • Hospitals
    • Specialty Centers
    • Ambulatory Surgical Centers
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Johnson & Johnson Services, Inc.
  • Gilead Sciences, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Janssen Pharmaceuticals, Inc.
  • CELSION Corporation
  • Abbott
  • Ipsen Pharma
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global liposome drug delivery market in 2022?

It was valued at US$ 4.7 Bn in 2022.

How big will be the liposome drug delivery business by 2031?

It is projected to reach more than US$ 10.0 Bn by 2031.

What will be the CAGR of the liposome drug delivery industry during the forecast period?

It is anticipated to grow at a CAGR of 8.5% from 2023 to 2031.

Which are the key factors driving the liposome drug delivery sector?

Focus on reducing side effects & improving drug bioavailability, higher targeted drug delivery demand, and technological advancements in various therapeutic areas.

What was the share of the leading liposome drug delivery segment?

The liposomal doxorubicin product segment accounted for more than 40.0% share in 2022.

Which region will be lucrative for liposome drug delivery companies during the forecast period?

North America is expected to be highly lucrative region from 2023 to 2031.

Who are the prominent liposome drug delivery players?

Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Inc., CELSION Corporation, Abbott, Ipsen Pharma, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Liposome Drug Delivery Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Liposome Drug Delivery Market Analysis and Forecast, 2017-2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Technological Advancements

        5.2. Overview: Liposome Drug delivery Systems

        5.3. Regulatory Scenario

        5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    6. Global Liposome Drug Delivery Market Analysis and Forecast, by Liposome Structure

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Liposome Structure, 2017-2031

            6.3.1. Unilamellar Liposomes

                6.3.1.1. Small

                6.3.1.2. Large

            6.3.2. Multilamellar liposomes

            6.3.3. Others

        6.4. Market Attractiveness Analysis, by Liposome Structure

    7. Global Liposome Drug Delivery Market Analysis and Forecast, by Product

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Product, 2017-2031

            7.3.1. Liposomal Doxorubicin

            7.3.2. Liposomal Paclitaxel

            7.3.3. Liposomal Amphotericin B

            7.3.4. Others

        7.4. Market Attractiveness Analysis, by Product

    8. Global Liposome Drug Delivery Market Analysis and Forecast, by Technology

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Technology, 2017-2031

            8.3.1. Stealth Liposome Technology

            8.3.2. Non PEGylated Liposome Technology

            8.3.3. DepoFoam Liposome Technology

            8.3.4. Lysolipid Thermally Sensitive Liposome Technology

        8.4. Market Attractiveness Analysis, by Technology

    9. Global Liposome Drug Delivery Market Analysis and Forecast, by Application

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Application, 2017-2031

            9.3.1. Fungal Diseases

            9.3.2. Cancer Therapy

            9.3.3. Pain Management

            9.3.4. Viral Vaccines

            9.3.5. Photodynamic Therapy

            9.3.6. Others

        9.4. Market Attractiveness Analysis, by Application

    10. Global Liposome Drug Delivery Market Analysis and Forecast, by End-user

        10.1. Introduction & Definition

        10.2. Key Findings / Developments

        10.3. Market Value Forecast, by End-user, 2017-2031

            10.3.1. Hospitals

            10.3.2. Specialty Centers

            10.3.3. Ambulatory Surgical Centers

            10.3.4. Others

        10.4. Market Attractiveness Analysis, by End-user

    11. Global Liposome Drug Delivery Market Analysis and Forecast, by Region

        11.1. Key Findings

        11.2. Market Value Forecast, by Region

            11.2.1. North America

            11.2.2. Europe

            11.2.3. Asia Pacific

            11.2.4. Latin America

            11.2.5. Middle East & Africa

        11.3. Market Attractiveness Analysis, by Region

    12. North America Liposome Drug Delivery Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Liposome Structure, 2017-2031

            12.2.1. Unilamellar Liposomes

                12.2.1.1. Small

                12.2.1.2. Large

            12.2.2. Multilamellar liposomes

            12.2.3. Others

        12.3. Market Value Forecast, by Product, 2017-2031

            12.3.1. Liposomal Doxorubicin

            12.3.2. Liposomal Paclitaxel

            12.3.3. Liposomal Amphotericin B

            12.3.4. Others

        12.4. Market Value Forecast, by Technology, 2017-2031

            12.4.1. Stealth Liposome Technology

            12.4.2. Non PEGylated Liposome Technology

            12.4.3. DepoFoam Liposome Technology

            12.4.4. Lysolipid Thermally Sensitive Liposome Technology

        12.5. Market Value Forecast, by Application, 2017-2031

            12.5.1. Fungal Diseases

            12.5.2. Cancer Therapy

            12.5.3. Pain Management

            12.5.4. Viral Vaccines

            12.5.5. Photodynamic Therapy

            12.5.6. Others

        12.6. Market Value Forecast, by End-user, 2017-2031

            12.6.1. Hospitals

            12.6.2. Specialty Centers

            12.6.3. Ambulatory Surgical Centers

            12.6.4. Others

        12.7. Market Value Forecast, by Country, 2017-2031

            12.7.1. U.S.

            12.7.2. Canada

        12.8. Market Attractiveness Analysis

            12.8.1. By Liposome Structure

            12.8.2. By Product

            12.8.3. By Technology

            12.8.4. By Application

            12.8.5. By End-user

            12.8.6. By Country

    13. Europe Liposome Drug Delivery Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Liposome Structure, 2017-2031

            13.2.1. Unilamellar Liposomes

                13.2.1.1. Small

                13.2.1.2. Large

            13.2.2. Multilamellar liposomes

            13.2.3. Others

        13.3. Market Value Forecast, by Product, 2017-2031

            13.3.1. Liposomal Doxorubicin

            13.3.2. Liposomal Paclitaxel

            13.3.3. Liposomal Amphotericin B

            13.3.4. Others

        13.4. Market Value Forecast, by Technology, 2017-2031

            13.4.1. Stealth Liposome Technology

            13.4.2. Non PEGylated Liposome Technology

            13.4.3. DepoFoam Liposome Technology

            13.4.4. Lysolipid Thermally Sensitive Liposome Technology

        13.5. Market Value Forecast, by Application, 2017-2031

            13.5.1. Fungal Diseases

            13.5.2. Cancer Therapy

            13.5.3. Pain Management

            13.5.4. Viral Vaccines

            13.5.5. Photodynamic Therapy

            13.5.6. Others

        13.6. Market Value Forecast, by End-user, 2017-2031

            13.6.1. Hospitals

            13.6.2. Specialty Centers

            13.6.3. Ambulatory Surgical Centers

            13.6.4. Others

        13.7. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.7.1. Germany

            13.7.2. U.K

            13.7.3. France

            13.7.4. Italy

            13.7.5. Spain

            13.7.6. Rest of Europe

        13.8. Market Attractiveness Analysis

            13.8.1. By Liposome Structure

            13.8.2. By Product

            13.8.3. By Technology

            13.8.4. By Application

            13.8.5. By End-user

            13.8.6. By Country/Sub-region

    14. Asia Pacific Liposome Drug Delivery Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast By Liposome Structure, 2017-2031

            14.2.1. Unilamellar Liposomes

                14.2.1.1. Small

                14.2.1.2. Large

            14.2.2. Multilamellar liposomes

            14.2.3. Others

        14.3. Market Value Forecast, by Product, 2017-2031

            14.3.1. Liposomal Doxorubicin

            14.3.2. Liposomal Paclitaxel

            14.3.3. Liposomal Amphotericin B

            14.3.4. Others

        14.4. Market Value Forecast, by Technology, 2017-2031

            14.4.1. Stealth Liposome Technology

            14.4.2. Non PEGylated Liposome Technology

            14.4.3. DepoFoam Liposome Technology

            14.4.4. Lysolipid Thermally Sensitive Liposome Technology

        14.5. Market Value Forecast, by Application, 2017-2031

            14.5.1. Fungal Diseases

            14.5.2. Cancer Therapy

            14.5.3. Pain Management

            14.5.4. Viral Vaccines

            14.5.5. Photodynamic Therapy

            14.5.6. Others

        14.6. Market Value Forecast, by End-user, 2017-2031

            14.6.1. Hospitals

            14.6.2. Specialty Centers

            14.6.3. Ambulatory Surgical Centers

            14.6.4. Others

        14.7. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.7.1. China

            14.7.2. Japan

            14.7.3. India

            14.7.4. Australia & New Zealand

            14.7.5. Rest of Asia Pacific

        14.8. Market Attractiveness Analysis

            14.8.1. By Liposome Structure

            14.8.2. By Product

            14.8.3. By Technology

            14.8.4. By Application

            14.8.5. By End-user

            14.8.6. By Country/Sub-region

    15. Latin America Liposome Drug Delivery Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Liposome Structure, 2017-2031

            15.2.1. Unilamellar Liposomes

                15.2.1.1. Small

                15.2.1.2. Large

            15.2.2. Multilamellar liposomes

            15.2.3. Others

        15.3. Market Value Forecast, by Product, 2017-2031

            15.3.1. Liposomal Doxorubicin

            15.3.2. Liposomal Paclitaxel

            15.3.3. Liposomal Amphotericin B

            15.3.4. Others

        15.4. Market Value Forecast, by Technology, 2017-2031

            15.4.1. Stealth Liposome Technology

            15.4.2. Non PEGylated Liposome Technology

            15.4.3. DepoFoam Liposome Technology

            15.4.4. Lysolipid Thermally Sensitive Liposome Technology

        15.5. Market Value Forecast, by Application, 2017-2031

            15.5.1. Fungal Diseases

            15.5.2. Cancer Therapy

            15.5.3. Pain Management

            15.5.4. Viral Vaccines

            15.5.5. Photodynamic Therapy

            15.5.6. Others

        15.6. Market Value Forecast, by End-user, 2017-2031

            15.6.1. Hospitals

            15.6.2. Specialty Centers

            15.6.3. Ambulatory Surgical Centers

            15.6.4. Others

        15.7. Market Value Forecast, by Country/Sub-region, 2017-2031

            15.7.1. Brazil

            15.7.2. Mexico

            15.7.3. Rest of Latin America

        15.8. Market Attractiveness Analysis

            15.8.1. By Liposome Structure

            15.8.2. By Product

            15.8.3. By Technology

            15.8.4. By Application

            15.8.5. By End-user

            15.8.6. By Country/Sub-region

    16. Middle East & Africa Liposome Drug Delivery Market Analysis and Forecast

        16.1. Introduction

            16.1.1. Key Findings

        16.2. Market Value Forecast, by Liposome Structure, 2017-2031

            16.2.1. Unilamellar Liposomes

                16.2.1.1. Small

                16.2.1.2. Large

            16.2.2. Multilamellar liposomes

            16.2.3. Others

        16.3. Market Value Forecast, by Product, 2017-2031

            16.3.1. Liposomal Doxorubicin

            16.3.2. Liposomal Paclitaxel

            16.3.3. Liposomal Amphotericin B

            16.3.4. Others

        16.4. Market Value Forecast, by Technology, 2017-2031

            16.4.1. Stealth Liposome Technology

            16.4.2. Non PEGylated Liposome Technology

            16.4.3. DepoFoam Liposome Technology

            16.4.4. Lysolipid Thermally Sensitive Liposome Technology

        16.5. Market Value Forecast, by Application, 2017-2031

            16.5.1. Fungal Diseases

            16.5.2. Cancer Therapy

            16.5.3. Pain Management

            16.5.4. Viral Vaccines

            16.5.5. Photodynamic Therapy

            16.5.6. Others

        16.6. Market Value Forecast, by End-user, 2017-2031

            16.6.1. Hospitals

            16.6.2. Specialty Centers

            16.6.3. Ambulatory Surgical Centers

            16.6.4. Others

        16.7. Market Value Forecast, by Country/Sub-region, 2017-2031

            16.7.1. GCC Countries

            16.7.2. South Africa

            16.7.3. Rest of Middle East & South Africa

        16.8. Market Attractiveness Analysis

            16.8.1. By Liposome Structure

            16.8.2. By Product

            16.8.3. By Technology

            16.8.4. By Application

            16.8.5. By End-user

            16.8.6. By Country/Sub-region

    17. Competition Landscape

        17.1. Market Player - Competition Matrix, by tier and size of companies

        17.2. Market Share Analysis, by Company, 2021

        17.3. Company Profiles

            17.3.1. Johnson & Johnson Services, Inc.

                17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.1.2. Product Portfolio

                17.3.1.3. Financial Overview

                17.3.1.4. SWOT Analysis

                17.3.1.5. Strategic Overview

            17.3.2. Gilead Sciences, Inc.

                17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.2.2. Product Portfolio

                17.3.2.3. Financial Overview

                17.3.2.4. SWOT Analysis

                17.3.2.5. Strategic Overview

            17.3.3. Sun Pharmaceutical Industries Ltd.

                17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.3.2. Product Portfolio

                17.3.3.3. Financial Overview

                17.3.3.4. SWOT Analysis

                17.3.3.5. Strategic Overview

            17.3.4. Novartis AG

                17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.4.2. Product Portfolio

                17.3.4.3. Financial Overview

                17.3.4.4. SWOT Analysis

                17.3.4.5. Strategic Overview

            17.3.5. Teva Pharmaceutical Industries Ltd

                17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.5.2. Product Portfolio

                17.3.5.3. Financial Overview

                17.3.5.4. SWOT Analysis

                17.3.5.5. Strategic Overview

            17.3.6. Janssen Pharmaceuticals, Inc.

                17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.6.2. Product Portfolio

                17.3.6.3. Financial Overview

                17.3.6.4. SWOT Analysis

                17.3.6.5. Strategic Overview

            17.3.7. CELSION Corporation

                17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.7.2. Product Portfolio

                17.3.7.3. Financial Overview

                17.3.7.4. SWOT Analysis

                17.3.7.5. Strategic Overview

            17.3.8. Abbott

                17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.8.2. Product Portfolio

                17.3.8.3. Financial Overview

                17.3.8.4. SWOT Analysis

                17.3.8.5. Strategic Overview

            17.3.9. Ipsen Pharma

                17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.9.2. Product Portfolio

                17.3.9.3. Financial Overview

                17.3.9.4. SWOT Analysis

                17.3.9.5. Strategic Overview

            17.3.10. Spectrum Pharmaceuticals, Inc.

                17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.10.2. Product Portfolio

                17.3.10.3. Financial Overview

                17.3.10.4. SWOT Analysis

                17.3.10.5. Strategic Overview

            17.3.11. Takeda Pharmaceutical Company Limited

                17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                17.3.11.2. Product Portfolio

                17.3.11.3. Financial Overview

                17.3.11.4. SWOT Analysis

                17.3.11.5. Strategic Overview

    List of Tables

    Table 01: Pipeline Analysis - Liposome Drug Delivery Systems

    Table 02: Clinically Marketed Liposome Drugs

    Table 03: Regulations - Principle difference between U.S., EU and India

    Table 04: Regulatory Scenario Assessment - Administrative Requirements

    Table 05: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027

    Table 06: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027

    Table 07: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027

    Table 08: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Region, 2017-2027

    Table 09: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country, 2017-2027

    Table 10: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027

    Table 11: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027

    Table 12: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027

    Table 13: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 14: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027

    Table 15: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027

    Table 16: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027

    Table 17: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 18: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027

    Table 19: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027

    Table 20: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027

    Table 21: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 22: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027

    Table 23: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027

    Table 24: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027

    Table 25: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 26: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017-2027

    Table 27: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017-2027

    Table 28: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017-2027

    List of Figures

    Figure 01: Global Liposome Drug Delivery Market Snapshot

    Figure 02: Global Liposome Drug Delivery Market Value (US$ Mn), by Region, 2022 and 2031

    Figure 03: Therapeutic applications of liposomes in drug delivery

    Figure 04: Advantages of liposome drug delivery system

    Figure 05: Global Liposome Drug Delivery Market Value (US$ Mn) and Y-o-Y (%) Forecast, 2017-2027

    Figure 06: Global Liposome Drug Delivery Market Value Share, by Product, 2022

    Figure 07: Global Liposome Drug Delivery Market Value Share, by Technology, 2022

    Figure 08: Global Liposome Drug Delivery Market Value Share, by Application, 2022

    Figure 09: Global Liposome Drug Delivery Market Value Share, by Region, 2022

    Figure 10: Regulatory Approval Process - U.S.

    Figure 11: Regulatory Approval Process - Europe

    Figure 12: Regulatory Approval Process - India

    Figure 13: Global Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031

    Figure 14: Global Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031

    Figure 15: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Doxorubicin, 2017-2027

    Figure 16: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Paclitaxel, 2017-2027

    Figure 17: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Amphotericin B, 2017-2027

    Figure 18: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

    Figure 19: Global Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 20: Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031

    Figure 21: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stealth Liposome Technology, 2017-2027

    Figure 22: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Non-PEGylated Liposome Technology, 2017-2027

    Figure 23: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DepoFoam Liposome Technology, 2017-2027

    Figure 24: Global Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031

    Figure 25: Global Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031

    Figure 26: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fungal Diseases, 2017-2027

    Figure 27: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pain Management, 2017-2027

    Figure 28: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer Therapy, 2017-2027

    Figure 29: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Viral Vaccines, 2017-2027

    Figure 30: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Photodynamic therapy, 2017-2027

    Figure 31: Global Liposome Drug Delivery Market - Regional Outlook

    Figure 32: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, 2017-2027

    Figure 33: Global Liposome Drug Delivery Market Value Share Analysis, by Region, 2022 and 2031

    Figure 34: Global Liposome Drug Delivery Market Attractiveness Analysis, by Region, 2017-2031

    Figure 35: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027

    Figure 36: North America Liposome Drug Delivery Market Value Share Analysis, by Country, 2022 and 2031

    Figure 37: North America Liposome Drug Delivery Market Attractiveness Analysis, by Country, 2017-2031

    Figure 38: North America Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031

    Figure 39: North America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031

    Figure 40: North America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 41: North America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031

    Figure 42: North America Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031

    Figure 43: North America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031

    Figure 44: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027

    Figure 45: Europe Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 46: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 47: Europe Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031

    Figure 48: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031

    Figure 49: Europe Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 50: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031

    Figure 51: Europe Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031

    Figure 52: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031

    Figure 53: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027

    Figure 54: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 55: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 56: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031

    Figure 57: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031

    Figure 58: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 59: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031

    Figure 60: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031

    Figure 61: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031

    Figure 62: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027

    Figure 63: Latin America Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 64: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 65: Latin America Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031

    Figure 66: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031

    Figure 67: Latin America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 68: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031

    Figure 69: Latin America Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031

    Figure 70: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031

    Figure 71: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027

    Figure 72: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 73: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 74: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Product, 2022 and 2031

    Figure 75: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2017-2031

    Figure 76: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 77: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2017-2031

    Figure 78: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Application, 2022 and 2031

    Figure 79: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2017-2031

Copyright © Transparency Market Research, Inc. All Rights reserved